Mural Oncology plc has announced its entry into an agreement to be acquired by XRA 5 Corp., a wholly owned subsidiary of XOMA Royalty, for a cash consideration of between $2.035 and $2.24 per share. This announcement follows a strategic review process aimed at maximizing shareholder value. Mural's Board supports the transaction, and the Mural Directors, who collectively represent a small percentage of the company's shares, have agreed to vote in favor of the acquisition. The Scheme Document, containing detailed information about the acquisition and related meetings, will be published soon.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mural Oncology plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9515452-en) on August 20, 2025, and is solely responsible for the information contained therein.